An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million

2 weeks ago 16

Cory Renauer, The Motley Fool

Sat, January 17, 2026 astatine 1:06 PM CST 5 min read

Acquisition of 588,235 shares astatine $17.00 per share, representing a full transaction worth of ~$10.0 cardinal arsenic of Jan. 9, 2026.
This acquisition represented 46.49% of Srinivas Akkaraju’s antecedently reported indirect holdings.
All shares are held indirectly via Samsara Opportunity Fund, L.P, with nary nonstop holdings reported post-transaction.
The transaction follows a bid of caller purchases, rapidly scaling vulnerability successful the discourse of beardown one-year banal appreciation (+206.29% arsenic of Jan. 16, 2026).
These 10 stocks could mint the adjacent question of millionaires ›

Srinivas Akkaraju, Director of Alumis (NASDAQ:ALMS), executed an open-market acquisition of 588,235 shares for a full information of ~$10.0 cardinal connected Jan. 9, 2026, according to the SEC Form 4 filing.

Metric

Value

Shares traded	588,235
Transaction value	$9,999,995.00
Post-transaction shares (direct)
Post-transaction shares (indirect)	1,853,488
Post-transaction worth (direct ownership)	$0.00

Transaction worth based connected SEC Form 4 reported terms ($17.00).

How important is this transaction comparative to Srinivas Akkaraju’s humanities trading successful Alumis?
This acquisition ranks among the largest connected grounds for this insider, with the 588,235 shares acquired exceeding the humanities median commercialized size of ~186,000 shares and raising cumulative indirect holdings by astir 47% successful a azygous event.
What is the operation of ownership for these shares?
All shares from this transaction are held indirectly done Samsara Opportunity Fund, L.P., arsenic elaborate successful the SEC filing footnotes, with Srinivas Akkaraju exercising voting and concern powerfulness done the fund’s wide partner.
How does the commercialized terms comparison to caller marketplace levels?
The acquisition was executed astatine $17.00 per share, a notable discount to some the Jan. 9, 2026 marketplace unfastened ($18.50) and adjacent ($19.56), and further beneath the $23.86 terms arsenic of Jan. 16, 2026, reflecting a favorable introduction comparative to consequent terms action.
What does this transaction bespeak regarding capableness and cadence?
The sizable acquisition follows a bid of incremental accumulations implicit the preceding 2 months, suggesting the insider is rapidly gathering vulnerability arsenic disposable capableness allows and successful the discourse of robust banal appreciation implicit the past year.

Metric

Value

Price (as of marketplace adjacent 1/9/26)	$17.00
Market capitalization	$2.49 billion
Revenue (TTM)	$22.12 million
1-year terms change	206.29%

* 1-year terms alteration calculated utilizing Jan. 9, 2026 arsenic the notation date.

Develops clinical-stage biopharmaceutical products targeting autoimmune and neuroinflammatory diseases, including ESK-001 and A-005, focused connected allosteric TYK2 inhibition.
Operates a research-driven model, generating gross done the improvement and imaginable commercialization of caller therapeutics for high-need indications.
Targets healthcare providers, specialists, and biopharma partners addressing autoimmune and neurodegenerative conditions.